Core Insights - Eddycon Holdings announced the signing of a definitive share purchase agreement to acquire all issued shares of Crown Bioscience International for a base consideration of $204 million, which includes performance-based payments [1] - The transaction is expected to be completed by mid-2026, with adjustments based on customary post-closing conditions [1] - Crown Bioscience is a global contract research organization (CRO) focused on drug discovery, preclinical, and translational research, particularly in oncology and immuno-oncology [1] Company Strategy - The acquisition aims to leverage the growing demand for precision diagnostics in China and the global biopharmaceutical innovation trends, presenting dual growth opportunities for Eddycon [1] - Post-acquisition, Crown Bioscience will operate as an independent entity under Eddycon, maintaining its research leadership and global client relationships while utilizing Eddycon's resources for further development [1] Financial Details - The total purchase price of $204 million includes a one-time profit payment of up to $40 million and a second profit payment of up to $44 million, contingent on the target group's adjusted EBITDA [1]
艾迪康控股：拟以2.04亿美元收购冠科生物，打造全球端到端实验室服务平台